Net revenue is expected to be $295 million-$303 million in the second quarter, versus a consensus of $301.65 million, including Sublocade sales of $188 million to $196 million and Perseris sales ...

The company faces competition, especially from Brixadi, impacting Sublocade's market share and growth, and has discontinued Perseris due to financial viability concerns. 2025 revenue is projected ...

Discontinuing sales and marketing for PERSERIS due to expected adverse impacts from increased payor management of the category that crystalized in Q2 and that are expected to make the product no ...

Indivior also said it was taking "decisive action that we believe is in the best interest of shareholders" by discontinuing sales of Perseris. However, “longer term, Indivior still expects to ...

The Richmond, Virginia-based company will discontinue sales of Perseris, despite it achieving a sales increase of 50% last year to $42 million. The grounding of Perseris will save the company $50 ...

New data presented by Teva at ECNP 2024 * demonstrate switching to UZEDY at four weeks after the last dose of once-monthly Perseris ® (RBP-7000) provided the most comparable pharmacokinetic (PK ...

Lowers annual profit forecast Cuts opioid treatment drug Sublocade's near term revenue Discontinues schizophrenia drug Perseris Shares down more than 40% July 9 (Reuters) - Drugmaker Indivior Plc ...

Indivior reaffirmed its medium-term financial outlook, projecting double-digit net revenue growth and operating margin expansion. Indivior has also reached a settlement agreement with end payor ...

Perseris manufacturer announced in July 2024 the discontinuation of its commercialization. Teva already presented in June 2024 data informing clinical strategies for switching patients to UZEDY ...